Found 10 hits in this display Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
Activin receptor type-1
(Homo sapiens (Human)) | BDBM148349
(US10017516, Compound 23 | US9682983, 23)Show SMILES NC(=O)c1cccc2c(ccnc12)-c1cnn2cc(cnc12)-c1ccc(cc1)N1CCNCC1 Show InChI InChI=1S/C26H23N7O/c27-25(34)22-3-1-2-21-20(8-9-29-24(21)22)23-15-31-33-16-18(14-30-26(23)33)17-4-6-19(7-5-17)32-12-10-28-11-13-32/h1-9,14-16,28H,10-13H2,(H2,27,34) | PDB
KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 26 | n/a | n/a | n/a | n/a | 7.5 | n/a |
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
| Assay Description Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2... |
US Patent US9682983 (2017)
BindingDB Entry DOI: 10.7270/Q28S4N3R |
More data for this Ligand-Target Pair | |
Activin receptor type-1
(Homo sapiens (Human)) | BDBM148349
(US10017516, Compound 23 | US9682983, 23)Show SMILES NC(=O)c1cccc2c(ccnc12)-c1cnn2cc(cnc12)-c1ccc(cc1)N1CCNCC1 Show InChI InChI=1S/C26H23N7O/c27-25(34)22-3-1-2-21-20(8-9-29-24(21)22)23-15-31-33-16-18(14-30-26(23)33)17-4-6-19(7-5-17)32-12-10-28-11-13-32/h1-9,14-16,28H,10-13H2,(H2,27,34) | PDB
KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 26 | n/a | n/a | n/a | n/a | n/a | n/a |
The Brigham and Women's Hospital, Inc.
US Patent
| Assay Description Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ... |
US Patent US10017516 (2018)
BindingDB Entry DOI: 10.7270/Q20P12CN |
More data for this Ligand-Target Pair | |
Serine/threonine-protein kinase receptor R3
(Homo sapiens (Human)) | BDBM148349
(US10017516, Compound 23 | US9682983, 23)Show SMILES NC(=O)c1cccc2c(ccnc12)-c1cnn2cc(cnc12)-c1ccc(cc1)N1CCNCC1 Show InChI InChI=1S/C26H23N7O/c27-25(34)22-3-1-2-21-20(8-9-29-24(21)22)23-15-31-33-16-18(14-30-26(23)33)17-4-6-19(7-5-17)32-12-10-28-11-13-32/h1-9,14-16,28H,10-13H2,(H2,27,34) | PDB MMDB
KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 52 | n/a | n/a | n/a | n/a | 7.5 | n/a |
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
| Assay Description Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2... |
US Patent US9682983 (2017)
BindingDB Entry DOI: 10.7270/Q28S4N3R |
More data for this Ligand-Target Pair | |
Serine/threonine-protein kinase receptor R3
(Homo sapiens (Human)) | BDBM148349
(US10017516, Compound 23 | US9682983, 23)Show SMILES NC(=O)c1cccc2c(ccnc12)-c1cnn2cc(cnc12)-c1ccc(cc1)N1CCNCC1 Show InChI InChI=1S/C26H23N7O/c27-25(34)22-3-1-2-21-20(8-9-29-24(21)22)23-15-31-33-16-18(14-30-26(23)33)17-4-6-19(7-5-17)32-12-10-28-11-13-32/h1-9,14-16,28H,10-13H2,(H2,27,34) | PDB MMDB
KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 52 | n/a | n/a | n/a | n/a | n/a | n/a |
The Brigham and Women's Hospital, Inc.
US Patent
| Assay Description Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ... |
US Patent US10017516 (2018)
BindingDB Entry DOI: 10.7270/Q20P12CN |
More data for this Ligand-Target Pair | |
Bone morphogenetic protein receptor type-1B
(Homo sapiens (Human)) | BDBM148349
(US10017516, Compound 23 | US9682983, 23)Show SMILES NC(=O)c1cccc2c(ccnc12)-c1cnn2cc(cnc12)-c1ccc(cc1)N1CCNCC1 Show InChI InChI=1S/C26H23N7O/c27-25(34)22-3-1-2-21-20(8-9-29-24(21)22)23-15-31-33-16-18(14-30-26(23)33)17-4-6-19(7-5-17)32-12-10-28-11-13-32/h1-9,14-16,28H,10-13H2,(H2,27,34) | PDB
UniProtKB/SwissProt
antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 106 | n/a | n/a | n/a | n/a | n/a | n/a |
The Brigham and Women's Hospital, Inc.
US Patent
| Assay Description Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ... |
US Patent US10017516 (2018)
BindingDB Entry DOI: 10.7270/Q20P12CN |
More data for this Ligand-Target Pair | |
Bone morphogenetic protein receptor type-1B
(Homo sapiens (Human)) | BDBM148349
(US10017516, Compound 23 | US9682983, 23)Show SMILES NC(=O)c1cccc2c(ccnc12)-c1cnn2cc(cnc12)-c1ccc(cc1)N1CCNCC1 Show InChI InChI=1S/C26H23N7O/c27-25(34)22-3-1-2-21-20(8-9-29-24(21)22)23-15-31-33-16-18(14-30-26(23)33)17-4-6-19(7-5-17)32-12-10-28-11-13-32/h1-9,14-16,28H,10-13H2,(H2,27,34) | PDB
UniProtKB/SwissProt
antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 106 | n/a | n/a | n/a | n/a | 7.5 | n/a |
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
| Assay Description Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2... |
US Patent US9682983 (2017)
BindingDB Entry DOI: 10.7270/Q28S4N3R |
More data for this Ligand-Target Pair | |
Bone morphogenetic protein receptor type-1A
(Homo sapiens (Human)) | BDBM148349
(US10017516, Compound 23 | US9682983, 23)Show SMILES NC(=O)c1cccc2c(ccnc12)-c1cnn2cc(cnc12)-c1ccc(cc1)N1CCNCC1 Show InChI InChI=1S/C26H23N7O/c27-25(34)22-3-1-2-21-20(8-9-29-24(21)22)23-15-31-33-16-18(14-30-26(23)33)17-4-6-19(7-5-17)32-12-10-28-11-13-32/h1-9,14-16,28H,10-13H2,(H2,27,34) | PDB
UniProtKB/SwissProt
antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 280 | n/a | n/a | n/a | n/a | 7.5 | n/a |
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
| Assay Description Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2... |
US Patent US9682983 (2017)
BindingDB Entry DOI: 10.7270/Q28S4N3R |
More data for this Ligand-Target Pair | |
Bone morphogenetic protein receptor type-1A
(Homo sapiens (Human)) | BDBM148349
(US10017516, Compound 23 | US9682983, 23)Show SMILES NC(=O)c1cccc2c(ccnc12)-c1cnn2cc(cnc12)-c1ccc(cc1)N1CCNCC1 Show InChI InChI=1S/C26H23N7O/c27-25(34)22-3-1-2-21-20(8-9-29-24(21)22)23-15-31-33-16-18(14-30-26(23)33)17-4-6-19(7-5-17)32-12-10-28-11-13-32/h1-9,14-16,28H,10-13H2,(H2,27,34) | PDB
UniProtKB/SwissProt
antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 280 | n/a | n/a | n/a | n/a | n/a | n/a |
The Brigham and Women's Hospital, Inc.
US Patent
| Assay Description Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ... |
US Patent US10017516 (2018)
BindingDB Entry DOI: 10.7270/Q20P12CN |
More data for this Ligand-Target Pair | |
Activin receptor type-1B
(Homo sapiens (Human)) | BDBM148349
(US10017516, Compound 23 | US9682983, 23)Show SMILES NC(=O)c1cccc2c(ccnc12)-c1cnn2cc(cnc12)-c1ccc(cc1)N1CCNCC1 Show InChI InChI=1S/C26H23N7O/c27-25(34)22-3-1-2-21-20(8-9-29-24(21)22)23-15-31-33-16-18(14-30-26(23)33)17-4-6-19(7-5-17)32-12-10-28-11-13-32/h1-9,14-16,28H,10-13H2,(H2,27,34) | PDB MMDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 1.52E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
The Brigham and Women's Hospital, Inc.
US Patent
| Assay Description Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE® Ultra ULight technology (Perkin Elmer) against ... |
US Patent US10017516 (2018)
BindingDB Entry DOI: 10.7270/Q20P12CN |
More data for this Ligand-Target Pair | |
Activin receptor type-1B
(Homo sapiens (Human)) | BDBM148349
(US10017516, Compound 23 | US9682983, 23)Show SMILES NC(=O)c1cccc2c(ccnc12)-c1cnn2cc(cnc12)-c1ccc(cc1)N1CCNCC1 Show InChI InChI=1S/C26H23N7O/c27-25(34)22-3-1-2-21-20(8-9-29-24(21)22)23-15-31-33-16-18(14-30-26(23)33)17-4-6-19(7-5-17)32-12-10-28-11-13-32/h1-9,14-16,28H,10-13H2,(H2,27,34) | PDB MMDB
Reactome pathway KEGG
UniProtKB/SwissProt
B.MOAD DrugBank antibodypedia GoogleScholar AffyNet
| PC cid PC sid UniChem
| US Patent
| n/a | n/a | 1.52E+4 | n/a | n/a | n/a | n/a | 7.5 | n/a |
The Brigham and Women's Hospital, Inc.; Dept. of Health and Human Services, National Institutes of Health
US Patent
| Assay Description Specifically, compounds were assayed using LANCE® Ultra ULight¿ technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2... |
US Patent US9682983 (2017)
BindingDB Entry DOI: 10.7270/Q28S4N3R |
More data for this Ligand-Target Pair | |